By Ben Glickman Shares of Repligen Corp. rose after the company logged an unexpected profit in the third quarter. The stock was up 19% to $135.64 in Tuesday.
Repligen Co. (NASDAQ:RGEN – Free Report) – Stock analysts at Zacks Research decreased their Q3 2023 EPS estimates for shares of Repligen in a note issued to investors on Thursday, October 26th. Zacks Research analyst S. Ganoria now expects that the biotechnology company will earn $0.18 per share for the quarter, down from their prior […]
Repligen (NASDAQ:RGEN – Free Report) had its price target cut by JPMorgan Chase & Co. from $200.00 to $180.00 in a research note released on Tuesday morning, Benzinga reports. They currently have an overweight rating on the biotechnology company’s stock. Several other equities analysts have also recently weighed in on RGEN. Stephens lifted their target […]
Geneva Capital Management LLC decreased its position in shares of Repligen Co. (NASDAQ:RGEN – Free Report) by 5.0% during the 2nd quarter, according to its most recent disclosure with the SEC. The firm owned 123,606 shares of the biotechnology company’s stock after selling 6,547 shares during the period. Geneva Capital Management LLC’s holdings in Repligen […]
Repligen Co. (NASDAQ:RGEN – Get Free Report)’s stock price traded up 4.6% during trading on Thursday . The company traded as high as $150.43 and last traded at $149.09. 156,091 shares traded hands during trading, a decline of 72% from the average session volume of 561,980 shares. The stock had previously closed at $142.51. Wall […]